137945-49-4

Basic information

• Product Name: IP-751,(3R,4R)-(DELTA6)-THC-DMH-11-OIC ACID
• Synonyms: IP-751,(3R,4R)-(DELTA6)-THC-DMH-11-OIC ACID
• CAS NO: 137945-49-4
• Molecular Formula: C₃₁H₅₀O₄Si
• Molecular Weight: 514.81
• Mol File: 137945-49-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: IP-751,(3R,4R)-(DELTA6)-THC-DMH-11-OIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: IP-751,(3R,4R)-(DELTA6)-THC-DMH-11-OIC ACID(137945-49-4)
• EPA Substance Registry System: IP-751,(3R,4R)-(DELTA6)-THC-DMH-11-OIC ACID(137945-49-4)

Safety Data

• Hazardous Substances Data: 137945-49-4(Hazardous Substances Data)

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 137945-48-3 ajulemic acid 
• 137945-54-1 2,2-Dimethyl-propionic acid (6aR,10aR)-1-(tert-butyl-dimethyl-silanyloxy)-3-(1,1-dimethyl-heptyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-ylmethyl ester 
• 137945-53-0 [(6aR,10aR)-1-(tert-Butyl-dimethyl-silanyloxy)-3-(1,1-dimethyl-heptyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]-methanol 
• 113418-02-3 2,2-Dimethyl-propionic acid (6aR,10aR)-3-(1,1-dimethyl-heptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-ylmethyl ester 
• 137945-57-4 (6aR,10aR)-1-(tert-Butyl-dimethyl-silanyloxy)-3-(1,1-dimethyl-heptyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carbaldehyde 

Downstream Products

• 137945-48-3 ajulemic acid 

Relevant articles and documents

CANNABINOIDS AND USES THEREOF

The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.

Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids

The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.